<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04698941</url>
  </required_header>
  <id_info>
    <org_study_id>2020LY021</org_study_id>
    <nct_id>NCT04698941</nct_id>
  </id_info>
  <brief_title>Combined Simvastatin and Albumin Paclitaxel in Treating ES-SCLC Patients Relapsed From 1st Chemotherapy</brief_title>
  <official_title>Clinical Study of Albumin Paclitaxel With or Without Simvastatin in Treating Extensive-Stage Small Cell Lung Cancer Patients Relapsed From First-line Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Pulmonary Hospital, Shanghai, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chinese Academy of Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Pulmonary Hospital, Shanghai, China</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase II study was designed to evaluate the safety and efficacy of albumin paclitaxel in&#xD;
      combination with simvastatin compared with treatment with albumin paclitaxel alone in ES-SCLC&#xD;
      patients relapsed from first-line chemotherapy. Participants will be divided in a 1:1 ratio&#xD;
      to receive either albumin paclitaxel (4 cycles) + simvastatin (10 months) or albumin&#xD;
      paclitaxel (4 cycles) until progressive disease (PD) as assessed by the investigator using&#xD;
      Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) or symptomatic&#xD;
      deterioration.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I.To assess disease control rate (DCR) after treatment.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I.To assess best overall response rate (ORR) after treatment. II.To evaluate the&#xD;
      progression-free survival (PFS) of patients with extensive stage-small cell lung cancer&#xD;
      (ES-SCLC) treated with albumin paclitaxel + simvastatin or with albumin paclitaxel alone.&#xD;
&#xD;
      III.To estimate overall survival (OS) of patients with ES-SCLC. IV. To evaluate the toxicity&#xD;
      profile of albumin paclitaxel + simvastatin.&#xD;
&#xD;
      EXPLORATORY OBJECTIVES:&#xD;
&#xD;
      I.To evaluate biomarkers correlatives. II.To explore the mechanism of albumin paclitaxel +&#xD;
      simvastatin in the treatment of chemotherapy-resistant participants with ES-SCLC.&#xD;
&#xD;
      OUTLINE: Patients are divided into two arms. ARM A: Participants received intravenous&#xD;
      infusions of albumin paclitaxel 260 milligrams per square meter (mg/m^2) on Day 1 of every&#xD;
      21-day cycle in combination with oral simvastatin (20mg daily) until persistent radiographic&#xD;
      PD as assessed by the investigator using Response Evaluation Criteria in Solid Tumors Version&#xD;
      1.1 (RECIST v1.1) or symptomatic deterioration.&#xD;
&#xD;
      ARM B:Participants received intravenous infusions of albumin paclitaxel 260 mg/m^2 alone on&#xD;
      Day 1 of every 21-day cycle until persistent radiographic PD, symptomatic deterioration,&#xD;
      intolerable toxicity, withdrawal of consent, death, or study termination by the Sponsor.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 25, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>6 weeks</time_frame>
    <description>To assess disease control rate (DCR) after treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>6 weeks</time_frame>
    <description>To assess best overall response rate (ORR) after treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>12 weeks</time_frame>
    <description>To evaluate the progression-free survival (PFS) of patients with extensive stage small cell lung cancer (ES-SCLC) treated with paclitaxel + simvastatin or with paclitaxel alone.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>24 weeks</time_frame>
    <description>To estimate overall survival (OS) of patients with ES-SCLC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events (AE) as assessed by CTCAE v4.0</measure>
    <time_frame>24 weeks</time_frame>
    <description>To evaluate the toxicity profile.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Simvastatin + Albumin Paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>received intravenous infusions of Paclitaxel 260 milligrams per square meter (mg/m^2) on Day 1 of every 21-day cycle (4 cycles) in combination with oral simvastatin (20mg daily) (10 months)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Albumin Paclitaxel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>received intravenous infusions of Paclitaxel 260 milligrams per square meter (mg/m^2) on Day 1 of every 21-day cycle (4 cycles)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Albumin Paclitaxel</intervention_name>
    <description>Albumin Paclitaxel intravenous infusion was administered at a dose of 260 mg/m^2 on Day 1 of each 21-day cycle.</description>
    <arm_group_label>Albumin Paclitaxel</arm_group_label>
    <arm_group_label>Simvastatin + Albumin Paclitaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
    <description>20mg daily oral tablet taken.</description>
    <arm_group_label>Simvastatin + Albumin Paclitaxel</arm_group_label>
    <other_name>Simvastatin Tablets</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients must be volunteered to participate in the clinical trial. Patients must sign&#xD;
             the informed Consent form (ICF) and be willing to follow and be able to complete all&#xD;
             test procedures.&#xD;
&#xD;
          2. Histologically or cytologically confirmed ES-SCLC (per the Veterans Administration&#xD;
             Lung Study Group [VALG] staging system).&#xD;
&#xD;
          3. No patients with resectable or radical radiotherapy lung cancer.&#xD;
&#xD;
          4. Patient must have no Epidermal Growth Factor Receptor (EGFR) mutation, Anaplastic&#xD;
             lymphoma kinase (ALK) rearrangement, or ROS proto-oncogene 1 , receptor tyrosine&#xD;
             kinase(ROS1) rearrangement.&#xD;
&#xD;
          5. Patient must be at least resistant to the first-line chemotherapy.&#xD;
&#xD;
          6. Patients must have measurable disease based on Response Evaluation Criteria in Solid&#xD;
             Tumors (RECIST) 1.1.&#xD;
&#xD;
          7. Patients can tolerate chemotherapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Unclear diagnosis of SCLC.&#xD;
&#xD;
          2. Resectable or radical radiotherapy SCLC.&#xD;
&#xD;
          3. Contraindicated chemotherapy.&#xD;
&#xD;
          4. Undergoing other active malignancies within 5 years or at the same time.Patients with&#xD;
             localized curable tumors, such as basal cell carcinoma, squamous cell carcinoma,&#xD;
             superficial bladder carcinoma, prostate carcinoma in situ, cervical carcinoma in situ,&#xD;
             or breast carcinoma in situ, will not be excluded.&#xD;
&#xD;
          5. Positive test result for human immunodeficiency virus (HIV).&#xD;
&#xD;
          6. Positive test result for active tuberculosis.&#xD;
&#xD;
          7. Live vaccine was administered within 28 days of initial administration. Inactivated&#xD;
             viral vaccines for seasonal influenza are allowed, except for live attenuated&#xD;
             intranasal vaccines.&#xD;
&#xD;
          8. Pregnant or lactating women.&#xD;
&#xD;
          9. A history of psychotropic substance abuse, drug abuse, or alcoholism.&#xD;
&#xD;
         10. Other factors assessed by the sponsors.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yayi He, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Pulmonary Hospital, Tongji University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hongbin Ji, PHD</last_name>
    <phone>+86-21-54921108</phone>
    <email>hbji@sibcb.ac.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200031</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hongbin Ji, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai pulmonary hospital, Tongji University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yayi He, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Goldman JW, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH, Garassino MC, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Każarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Thiyagarajah P, Jiang H, Paz-Ares L; CASPIAN investigators. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2021 Jan;22(1):51-65. doi: 10.1016/S1470-2045(20)30539-8. Epub 2020 Dec 4.</citation>
    <PMID>33285097</PMID>
  </reference>
  <reference>
    <citation>Gelsomino F, Tiseo M, Barbieri F, Riccardi F, Cavanna L, Frassoldati A, Delmonte A, Longo L, Dazzi C, Cinieri S, Colantonio I, Sperandi F, Lamberti G, Brocchi S, Tofani L, Boni L, Ardizzoni A. Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL). Br J Cancer. 2020 Jul;123(1):26-32. doi: 10.1038/s41416-020-0845-3. Epub 2020 Apr 29. Erratum in: Br J Cancer. 2021 Jul;125(2):306.</citation>
    <PMID>32346071</PMID>
  </reference>
  <reference>
    <citation>Chen Y, Li X, Zhang R, Xia Y, Shao Z, Mei Z. Effects of statin exposure and lung cancer survival: A meta-analysis of observational studies. Pharmacol Res. 2019 Mar;141:357-365. doi: 10.1016/j.phrs.2019.01.016. Epub 2019 Jan 11.</citation>
    <PMID>30641276</PMID>
  </reference>
  <reference>
    <citation>Khanzada UK, Pardo OE, Meier C, Downward J, Seckl MJ, Arcaro A. Potent inhibition of small-cell lung cancer cell growth by simvastatin reveals selective functions of Ras isoforms in growth factor signalling. Oncogene. 2006 Feb 9;25(6):877-87.</citation>
    <PMID>16170339</PMID>
  </reference>
  <reference>
    <citation>Holstein SA, Hohl RJ. Synergistic interaction of lovastatin and paclitaxel in human cancer cells. Mol Cancer Ther. 2001 Dec;1(2):141-9.</citation>
    <PMID>12467231</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>December 30, 2020</study_first_submitted>
  <study_first_submitted_qc>January 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 7, 2021</study_first_posted>
  <last_update_submitted>July 26, 2021</last_update_submitted>
  <last_update_submitted_qc>July 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Pulmonary Hospital, Shanghai, China</investigator_affiliation>
    <investigator_full_name>Yayi He</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>ES-SCLC</keyword>
  <keyword>Chemo-resistance</keyword>
  <keyword>Simvastatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

